Company intelligence / Profile preview
Orna Therapeutics
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Orna Therapeutics has presented robust preclinical data demonstrating that its engineered circular RNA (oRNA) and LNP delivery can generate potent and sustained in vivo CAR T cell activity for cancer and B cell–driven autoimmune diseases. The company has reported successful B cell depletion in non-human primates and is advancing its lead isCAR platform toward clinical trials[3][1].
- Therapeutic areas
- Infectious DiseasesImmunologyOncologyRare Diseases
- Modalities
- RNA therapymRNA-based drugsLipid nanoparticle delivery therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Merck (collaboration in infectious diseases)[3]
Beyond the preview
Go deeper on Orna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orna Therapeutics.